Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
ACM Research, Inc. (ACMR) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ACM Research, Inc. (ACMR) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for February 8th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 8:
Post Holdings, Inc. (POST - Free Report) : This consumer-packaged goods holding company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 9.2% over the last 60 days.
Post Holdings, Inc. Price and Consensus
Post Holdings, Inc. price-consensus-chart | Post Holdings, Inc. Quote
Post Holdings' shares gained 24% over the last three months compared with the S&P 500’s advance of 13.8%. The company possesses a Momentum Score of A.
Post Holdings, Inc. Price
Post Holdings, Inc. price | Post Holdings, Inc. Quote
Inhibikase Therapeutics, Inc. (IKT - Free Report) : This pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16% over the last 60 days.
Inhibikase Therapeutics, Inc. Price and Consensus
Inhibikase Therapeutics, Inc. price-consensus-chart | Inhibikase Therapeutics, Inc. Quote
Inhibikase Therapeutics' shares gained 172.1% over the last three months compared with the S&P 500’s advance of 13.8%. The company possesses a Momentum Score of A.
Inhibikase Therapeutics, Inc. Price
Inhibikase Therapeutics, Inc. price | Inhibikase Therapeutics, Inc. Quote
ACM Research, Inc. (ACMR - Free Report) : This semiconductor equipment company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.1% over the last 60 days.
ACM Research, Inc. Price and Consensus
ACM Research, Inc. price-consensus-chart | ACM Research, Inc. Quote
ACM Research's shares gained 23.1% over the last six months compared with the S&P 500’s advance of 10.9%. The company possesses a Momentum Score of A.
ACM Research, Inc. Price
ACM Research, Inc. price | ACM Research, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.